descovy
Selected indexed studies
- Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women. (N Engl J Med, 2024) [PMID:39046157]
- Bictegravir. (Curr Opin HIV AIDS, 2018) [PMID:29746268]
- Descovy Approved for HIV Prexposure Prophylaxis. (Am J Nurs, 2020) [PMID:31977410]
_Worker-drafted node — pending editorial review._
Connections
descovy is a side effect of
Sources
- Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. (2017) pubmed
- Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial. (2025) pubmed
- Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial. (2023) pubmed
- Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. (2020) pubmed
- Bictegravir. (2018) pubmed
- Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. (2020) pubmed
- Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial. (2021) pubmed
- Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women. (2024) pubmed
- Descovy Approved for HIV Prexposure Prophylaxis. (2020) pubmed
- Bioavailability of dissolved and crushed single tablets of bictegravir, emtricitabine, tenofovir alafenamide in healthy adults: the SOLUBIC randomized crossover study. (2022) pubmed